Wall Street analysts expect that Tricida Inc (NASDAQ:TCDA) will post earnings of ($0.89) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Tricida’s earnings, with the lowest EPS estimate coming in at ($0.91) and the highest estimate coming in at ($0.87). The business is expected to issue its next quarterly earnings results on Thursday, February 14th.
According to Zacks, analysts expect that Tricida will report full year earnings of ($2.92) per share for the current fiscal year, with EPS estimates ranging from ($2.94) to ($2.90). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.45) per share, with EPS estimates ranging from ($3.50) to ($3.39). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Tricida.
Tricida (NASDAQ:TCDA) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.19.
In other news, insider Claire Lockey sold 10,000 shares of the stock in a transaction that occurred on Wednesday, December 26th. The stock was sold at an average price of $25.06, for a total transaction of $250,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Geoffrey M. Parker purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 13th. The shares were purchased at an average cost of $29.72 per share, for a total transaction of $148,600.00. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 21,163 shares of company stock valued at $527,266.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Legal & General Group Plc acquired a new stake in Tricida in the third quarter worth $54,000. Vanguard Group Inc bought a new position in shares of Tricida in the third quarter worth $33,317,000. Vanguard Group Inc. bought a new position in shares of Tricida in the third quarter worth $33,317,000. TIAA CREF Investment Management LLC bought a new position in shares of Tricida in the third quarter worth $722,000. Finally, Teachers Advisors LLC bought a new position in shares of Tricida in the third quarter worth $667,000. 68.39% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ TCDA opened at $23.24 on Monday. Tricida has a 12 month low of $21.08 and a 12 month high of $40.10. The company has a quick ratio of 12.68, a current ratio of 12.68 and a debt-to-equity ratio of 0.11.
Tricida Company Profile
Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer drug that has completed Phase III clinical trials to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is headquartered in South San Francisco, California.
Further Reading: The Role of a Fiduciary and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.